BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Files An 8-K Results of Operations and Financial Condition
Item 2.02
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Files An 8-K Results of Operations and Financial Condition
BIODELIVERY SCIENCES INTERNATIONAL INC Exhibit
EX-99.1 2 a2021-03x10xxbdsixx4qinanc.htm EX-99.1 DocumentBioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million,…
To view the full exhibit click
EX-99.1 2 a2021-03x10xxbdsixx4qinanc.htm EX-99.1 DocumentBioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million,…
To view the full exhibit click
hereAbout BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
